In vitro analysis of nanoparticulate hydroxyapatite/chitosan composites as potential drug delivery platforms for the sustained release of antibiotics in the treatment of osteomyelitis

Journal of Pharmaceutical Sciences

Volumn 103, Issue 2, 2014, Pages 567-579

  Uskoković, Vuk ^a   Desai, Tejal A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiinfectives; Biomaterials; Calcium phosphate; Cell culture; Chitosan; Light scattering (dynamic); Nanoparticles; Osteoblast; Osteogenesis; Osteomyelitis; PCR

Indexed keywords

ANTIBIOTIC AGENT; CHITOSAN; DRUG CARRIER; FLUORESCEIN; HYDROXYAPATITE; NANOPARTICLE; OSTEOCALCIN; OSTEOPONTIN; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL SPREADING; COMPOSITE MATERIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GENE EXPRESSION; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOMYELITIS; POLYMERIZATION; RECEPTOR DOWN REGULATION; STAPHYLOCOCCUS AUREUS; SUSTAINED DRUG RELEASE; UPREGULATION;

ANTIINFECTIVES; BIOMATERIALS; CALCIUM PHOSPHATE; CELL CULTURE; CHITOSAN; LIGHT SCATTERING (DYNAMIC); NANOPARTICLES; OSTEOBLAST; OSTEOGENESIS; OSTEOMYELITIS; PCR;

3T3 CELLS; ALGORITHMS; ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CHITOSAN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DURAPATITE; LIGHT; MICE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; OSTEOMYELITIS; PARTICLE SIZE; REAL-TIME POLYMERASE CHAIN REACTION; SCATTERING, RADIATION; SPECTROPHOTOMETRY, ULTRAVIOLET; STAPHYLOCOCCUS AUREUS;

EID: 84895925622     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23824     Document Type: Article

References (92)

1. Gogia JS, Meehan JP, Di Cesare PE, Jamali AA. 2009. Local antibiotic therapy in osteomyelitis. Sem Plastic Surg 23(2):100-107.
2. Paluska SA. 2004. Osteomyelitis. Clin Fam Pract 6(1):127-156.
3. Yenson A, de Fries HO, Deeb ZE. 1983. Actinomycotic osteomyelitis of the facial bones and mandible. Otolaryngol Head Neck Surg 91(2):173-176.
4. Hatzenbuehler J, Pulling TJ. 2011. Diagnosis and management of osteomyelitis. Am Fam Phys 84(9):1027-1033.
5. Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. 2008. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty 23:984-991.
6. Bozic KJ, Kurtz SM, Lau E, Ong K, Chiu V, Vail TP, Rubash HE, Berry DJ. 2010. The epidemiology of revision total knee arthroplasty in the United States. Clin Orthop Relat Res 468(1):45-51.
7. Harris I, Lyons M. 2005. Reoperation rate in diaphyseal tibia fractures. ANZ J Surg 75, 1041-1044.
8. Uskoković V, Desai TA. 2013. Phase composition control of calcium phosphate nanoparticles for tunable drug delivery kinetics and treatment of osteomyelitis. Part 2: Antibacterial and osteoblastic response. J Biomed Mater Res A 101(5):1427-1436.
9. Uskoković V, Desai TA. 2013. Phase composition control of calcium phosphate nanoparticles for tunable drug delivery kinetics and treatment of osteomyelitis. Part 1: Preparation and drug release. J Biomed Mater Res A 101(5):1416-1426.
10. D'Este M, Eglin D. 2013. Hydrogels in calcium phosphate moldable and injectable bone substitutes: Sticky excipients or advanced 3-D carriers? Acta Biomater 9(2013):5421-5430.
11. Liu SQ. 2007. Bioregenerative engineering: Principles and applications. Hoboken, New Jersey: John Wiley & Sons.
12. Smelcerović A, Knezević-Jugović Z, Petronijević Z. 2008. Microbial polysaccharides and their derivatives as current and prospective pharmaceuticals. Curr Pharm Des 14:3168-3195.
13. Yin H, Du Y, Zhang J. 2009. Low molecular weight and oligomeric chitosans and their bioactivities. Curr Top Med Chem 9:1546-1559.
14. Arancibia R, Maturana C, Silva D, Tobar N, Tapia C, Salazar JC, Martínez J, Smith PC. 2013. Effects of chitosan particles in periodontal pathogens and gingival fibroblasts. J Dent Res 92:740-745.
15. Ing LY, Zin NM, Sarwar A, Katas H. 2012. Antifungal activity of chitosan nanoparticles and correlation with their physical properties. Int J Biomater 632698.
16. Berknop-Schnurch A, Dunnhaupt S. 2012. Chitosan-based drug delivery systems. Eur J Pharm Biopharm 81:463-469.
17. Singha K, Namgung R, Kim WJ. 2011. Polymers in smallinterfering RNA delivery. Nucleic Acid Ther 21:133-147.
18. Duceppe N, Tabrizian M. 2010. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin Drug Deliv 7:1191-1207.
19. Paul W, Sharma CP. 2008. Natural bioresorbable polymers. In Degradation rate of bioresorbable materials; Buchanan F, Ed. Cambridge, UK: Woodhead.
20. Yeh TH, Hsu LW, Tseng MT, Lee PL, Sonjae K, Ho YC, Sung HW. 2011. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 32(26):6164-6173.
21. Kowapradit J, Opanasopit P, Ngawhirunpat T, Rojanarata T, Ruktanonchai U, Sajomsang W. 2010. Methylated N-(4-N, Ndimethylaminocinnamyl) chitosan enhances paracellular permeability across Caco-2 cells. Drug Deliv 17(5):301-312.
22. Saper RB, Eisenberg DM, Phillips RS. 2004. Common dietary supplements for weight loss. Am Fam Physician 70(9):1731-1738.
23. Wilson Jr. OC, Hull JR. 2008. Surface modification of nanophase hydroxyapatite with chitosan. Mater Sci Eng C 28(3):434-437.
24. Lee HS, Tsai S, Kuo CC, Bassani AW, Pepe-Mooney B, Miksa D, Masters J, Sullivan R, Composto RJ. 2012. Chitosan adsorption on hydroxyapatite and its role in preventing acid erosion. J Colloid Interface Sci 385:235-243.
25. Chen J, Yu Q, Zhang G, Yang S, Wu J, Zhang Q. 2012. Preparation and biocompatibility of nanohybrid scaffolds by in situ homogeneous formation of nano hydroxyapatite from biopolymer polyelectrolyte complex for bone repair applications. Colloids Surf B Biointerfaces 93:100-107.
26. Tripathi A, Saravanan S, Pattnaik S, Moorthi A, Partridge NC, Selvamurugan N. 2012. Bio-composite scaffolds containing chitosan/ nanohydroxyapatite/ nano-copper-zinc for bone tissue engineering. Int J Biol Macromol 50(1):294-299.
27. Tanase CE, Popa MI, Verestiuc L. 2012. Biomimetic chitosancalcium phosphate composites with potential applications as bone substitutes: Preparation and characterization. J Biomed Mater Res B Appl Biomater 100(3):700-708.
28. Palazzo B, Gallo A, Casillo A, Nitti P, Ambrosio L, Piconi C. 2011. Fabrication, characterization and cell cultures on a novel composite chitosan-nano-hydroxyapatite scaffold. Int J Immunopathol Pharmacol 24(1 Suppl 2):73-78.
29. Thanyaphoo S, Kaewsrichan J. 2012. Synthesis and evaluation of novel glass ceramics as drug delivery systems in osteomyelitis. J Pharm Sci 101(8):2870-2882.
30. Zhang J, Wang C, Wang J, Qu Y, Liu G. 2012. In vivo drug release and antibacterial properties of vancomycin loaded hydroxyapatite/chitosan composite Drug Deliv 19, 264-269.
31. Ma T, Shang BC, Tang H, Zhou TH, Xu GL, Li HL, Chen QH, Xu YQ. 2011. Nano-hydroxyapatite/chitosan/konjac glucomannan scaffolds loaded with cationic liposomal vancomycin: Preparation, in vitro release and activity against Staphylococcus aureus biofilms. J Biomater Sci Polym Ed 22(12):1669-1681.
32. Shi P, Zuo Y, Li X, Zou Q, Liu H, Zhang L, Li Y, Morsi YS. 2010. Gentamicin-impregnated chitosan/nanohydroxyapatite/ethyl cellulose microspheres granules for chronic osteomyelitis therapy. J Biomed Mater Res A 93(3):1020-1031.
33. Zou Q, Li Y, Zhang L, Zuo Y, Li J, Li J. 2009. Antibiotic delivery system using nano-hydroxyapatite/chitosan bone cement consisting of berberine. J Biomed Mater Res A 89(4):1108-1117.
34. Fan J, Bi L, Wu T, Cao L, Wang D, Nan K, Chen J, Jin D, Jiang S, Pei G. 2012. A combined chitosan/nano-size hydroxyapatite system for the controlled release of icariin. J Mater Sci Mater Med 23(2):399-407.
35. Venkatesan P, Puvvada N, Dash R, Prashanth Kumar BN, Sarkar D, Azab B, Pathak A, Kundu SC, Fisher PB, Mandal M. 2011. The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials 32(15):3794-3806.
36. Liu TY, Chen SY, Li JH, Liu DM. 2006. Study on drug release behaviour of CDHA/chitosan nanocomposites-Effect of CDHA nanoparticles. J Control Release 112(1):88-95.
37. Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, Han BH, Kim MS, Shin CS, Kim SY. 2005. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone 37(3):359-369.
38. Rousseau M, Boulzaguet H, Biagianti J, Duplat D, Milet C, Lopez E, Bedouet L. 2007. Low molecular weight molecules of oyster nacre induce mineralization of the MC3T3-E1 cells. J Biomed Mat Res A 85A(2):487-497.
39. Celetti A, Testa D, Staibano S, Merolla F, Guarino V, Castellone MD, Iovine R, Mansueto G, Somma P, De Rosa G, Galli V, Melillo RM, Santoro M. 2005. Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res 11(22):8019-1027.
40. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acid Res 29:e45.
41. Onuma K, Ito A. 1998. Cluster growth model for hydroxyapatite. Chem Mater 10(11):3346-3351.
42. Combes C, Rey C. 2010. Amorphous calcium phosphates: Synthesis, properties and uses in biomaterials. Acta Biomater 6:3362-3378.
43. He G, Dahl T, Veis A, George A. 2003. Nucleation of apatite crystals in vitro by self-assembled dentin matrix protein 1. Nat Mater 2(8):552-558.
44. Fosca M, Komlev VS, Yu A, Fedotov R. Caminiti JV Rau. 2012. Structural study of octacalcium phosphate bone cement conversion in vitro. ACS Appl Mater Interface 4:6202-6210.
45. Lu HH, Pollack SR, Ducheyne P. 2000. Temporal zeta potential variations of 45S5 bioactive glass immersed in an electrolyte solution. J Biomed Mater Res 51(1):80-87.
46. Lee J, Yun KS, Choi CS, Shin SH, Ban HS, Rhim T, Lee SK, Lee KY. 2012. T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles. Bioconjug Chem. 23(6):1174-1180
47. Fazil M, Md S, Hague S, Kumar M, Baboota S, Sahni JK, Ali J. 2012. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 47:6-15.
48. Narayanan D, Anitha A, Jayakumar R, Nair SV, Chennazhi KP. 2012. Synthesis, characterization and preliminary in vitro evaluation of PTH 1-34 loaded chitosan nanoparticles for osteoporosis. J Biomed Nanotechnol 8:98-106.
49. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. 2010. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 62:59-82.
50. Hu CS, Chiang CH, Hong PD, Yeh MK. 2012. Influence of charge on FITC-BSA-loaded chondroitin sulfate-chitosan nanoparticles upon cell uptake in human Caco-2 cell monolayers. Int J Nanomed 7:4861-4872.
51. Uskoković V. 2012. Dynamic light scattering and microelectrophoresis: Main prospects and limitations. J Dispersion Sci Technol 33:1762-1786.
52. Caroni ALPF, de Lima CRM, Pereira MR, Fonseca JLC. 2012. Tetracycline adsorption on chitosan: A mechanistic description based on mass uptake and zeta potential measurements. Colloids Surf B 100:222-228.
53. Ranjan OP, Shavi GV, Nayak UY, Arumugam K, Averineni RK, Meka SR, Sureshwar P. 2011. Controlled release chitosan microspheres of mirtazapine: In vitro and In vivo evaluation. Arch Pharm Res 34:1919-1929.
54. Saremi S, Atyabi F, Akhlaghi SO, Ostad SN, Dinarvand R. 2011. Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: Preparation, in vitro and ex vivo evaluation. Int J Nanomed 6:119-128.
55. Rajam M, Pulavendran S, Rose C, Mandal AB. 2011. Chitosan nanoparticles as a dual growth factor delivery system for tissue engineering applications. Int J Pharm 410(1-2):145-152.
56. Kim H, Tator CH, Shoichet MS. 2011. Chitosan implants in the rat spinal cord: Biocompatibility and biodegradation. J Biomed Mater Res A 97:395-404.
57. Ren D, Yi H, Wang W, Ma X. 2005. The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylation. Carbohydr Res 340:2403-2410.
58. Correlo VM, Pinho ED, Pashkuleva I, Bhattacharya M, Neves NM, Reis RL. 2007. Water absorption and degradation characteristics of chitosan-based polyesters and hydroxyapatite composites. Macromol Biosci 7:354-363.
59. Zhou G, Li Y, Zhang L, Zuo Y, Jansen JA. 2007. Preparation and characterization of nano-hydroxyapatite/chitosan/konjac glucomannan composite J Biomed Mater Res Part A 83A(4):931-939.
60. Uskoković V, Hoover C, Vukomanović M, Uskoković DP, Desai TA. 2013. Osteogenic and antimicrobial nanoparticulate calcium phosphate and/or poly-lactide-co-glycolide powders for the treatment of osteomyelitis. Mater Sci Eng C 33(6):3362-3373.
61. Jarmila V, Vavrikova E. 2011. Chitosan derivatives with antimicrobial, antitumour and antioxidant activities-A review. Curr Pharm Des 17(32):3596-3607.
62. Ing LY, Zin NM, Sarwar A, Katas H. 2012. Antifungal activity of chitosan nanoparticles and correlation with their physical properties. Int J Biomater: 632698.
63. Chung Y-C, Su Y-P, Chen C-C, Jia G, Wang H-L, Wu JCG, Lin J-G. 2004. Relationship between antibacterial activity of chitosan and surface characteristics of cell wall. Acta Pharmacologica Sinica 25:932-936.
64. Butcher DT, Alliston T, Weaver VM. 2009. A tense situation: Forcing tumour progression. Nat Rev Cancer 9:108-122.
65. Uskoković PS, Tang CY, Tsui CP, Ignjatović N, Uskoković D. 2007. Micromechanical properties of a hydroxyapatite/poly-L- lactide biocomposite using nano-indentation and modulus mapping. J Europ Ceram Soc 27:1559-1564.
66. Fan H, Wang L, Zhao K, Li N, Shi Z, Ge Z, Jin Z. 2010. Fabrication, mechanical properties, and biocompatibility of graphene-reinforced chitosan composites. Biomacromolecules 11(9):2345-2351.
67. Liu H, Slamovich EB, Webster TJ. 2006. Increased osteoblast functions among nanophase titania/poly(lactide-co-glycolide) composites of the highest nanometer surface roughness. J Biomed Mater Res A 78:798-807.
68. Xu C, Yang F, Wang S, Ramakrishna S. 2004. In vitro study of human vascular endothelial cell function on materials with various surface roughness. J Biomed Mater Res A 71:154-161.
69. Rhoades J, Roller S. 2000. Antimicrobial actions of degraded and native chitosan against spoilage organisms in laboratory media and foods. Appl Environ Microbiol 66(1):80-86.
70. Jeevitha D, Amarnath K. 2013. Chitosan/PLA nanoparticles as a novel carrier for the delivery of anthraquinone: Synthesis, characterization and In vitro cytotoxicity evaluation Colloids Surf B 101(1):126-134.
71. Ma Z, Lim, LY. 2003. Uptake of chitosan and associated insulin in Caco-2 cell monolayers: A comparison between chitosan molecules and chitosan nanoparticles. Pharm Res. 20:1812-1819.
72. Loh JW, Saunders M, Lim LY. 2012. Cytotoxicity of monodispersed chitosan nanoparticles against the Caco-2 cells. Toxicol Appl Pharmacol 262(3):273-282.
73. Loh JW, Yeoh G, Saunders M, Lim LY. 2010. Uptake and cytotoxicity of chitosan nanoparticles in human liver cells. Toxicol Appl Pharmacol 249:148-157.
74. Loretz B, Bernkop-Schnurch A. 2007. In vitro cytotoxicty testing of non-thiolated and thiolated chitosan nanoparticles for oral gene delivery. Nanotoxicology 1:139-148.
75. Chae SY, Jang MK, Nah JW. 2005. Influence ofmolecular weight on oral absorption of water soluble chitosans. J Control Release 102:383-394.
76. Opanasopit P, Aumklad P, Kowapradit J, Ngawhiranpat T, Apirakaramwong A, Rojanarata T, Puttipipatkhachorn S. 2007. Effect of salt forms and molecular weight of chitosans on in vitro permeability enhancement in intestinal epithelial cells (Caco-2). Pharm Dev Technol 12:447-455.
77. Qi LF, Xu ZR, Li Y, Jiang X, Han XY. 2005. In vitro effects of chitosan nanoparticles on proliferation of human gastric carcinoma cell line MGC803 cells. World J Gastroenterol 11:5136-5141.
78. Carreno-Gomez B, Duncan R. 1997. Evaluation of the biological properties of soluble chitosan and chitosan microspheres. Int J Pharm 148:231-240.
79. Baldrick P. 2010. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 56:290-299.
80. Chaudhury A, Das S. 2011. Recent advancement of chitosan-based nanoparticles for oral controlled delivery of insulin and other therapeutic agents. AAPS Pharm Sci Tech 12:10-20.
81. Tanaka Y, Tanioka S, Tanaka M, Tanigawa T, Kitamura Y, Minami S, Okamoto Y, Miyashita M, Nanno M. 1997. Effects of chitin and chitosan particles on BALB/c mice by oral and parenteral administration. Biomaterials 18:591-595.
82. Cheng Q, Zhang J, Xia W. 2013. Prenatal and developmental effect of high molecular weight chitosan (HMWCS) to mice. Regul Toxicol Pharmacol 65(3):294-303.
83. Hu YL, Qi W, Han F, Shao JZ, Gao JQ. 2011. Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model. Int J Nanomed 6:3351-3359.
84. Peng H, Yin Z, Liu H, Chen X, Feng B, Yuan H, Su B, Ouyang H, Zhang Y. 2012. Electrospun biomimetic scaffold of hydroxyapatite/ chitosan supports enhanced osteogenic differentiation of mMSCs. Nanotechnology 23, 495102(10 pp).
85. Kim B-S, Kim JS, Chung YS, Sin Y-W, Ryu K-H, Lee J, You H-K. 2012. Growth and osteogenic differentiation of alveolar human bone marrow-derived mesenchymal stem cells on chitosan/hydroxyapatite composite fabric. J Biomed Mater Res A 101(6):1550-1558.
86. Phan TCA, Xu J, Zheng MH. 2004. Interaction between osteoblast and osteoclast: Impact in bone disease. Histol Histopathol 19:1325-1344.
87. Wenk H-R, Heidelbach F. 1999. Crystal alignment of carbonated apatite in bone and calcified tendon: Results from quantitative texture analysis. Bone 24:361-369.
88. Patel LN, Zaro JL, Shen WC. 2007. Cell penetrating peptides: Intracellular pathways and pharmaceutical perspectives. Pharm Res 24:1977-1992.
89. Huang W, Carlsen B, Rudkin G, Berry M, Ishida K, Yamaguchi DT, Miller TA. 2004. Osteopontin is a negative regulator of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells. Bone 34(5):799-808.
90. Mountziaris PM, Spicer PP, Kasper FK, Mikos AG. 2011. Harnessing and modulating inflammation in strategies for bone regeneration. Tissue Eng Part B Rev 17(6):393-402.
91. Benowitz LI, Popovich PG. 2011. Inflammation and axon regeneration. Curr Opin Neurol 24(6):577-583.
92. Thomas MV, Puleo DA. 2011. Infection, inflammation, and bone regeneration: A paradoxical relationship. J Dent Res 90(9):1052-1061.